A clinical-stage pharmaceutical company developing novel therapeutics to treat important diseases such as non-alcoholic steatohepatitis (NASH) and various cancers. Our expertise in FASN enables us to break new ground in targeting dysfunctional metabolic pathways.

body

We’ve created a platform of proprietary, selective FASN inhibitors. Our lead product candidate TVB-2640 is an oral, highly potent, selective and reversible, first-in-class FASN inhibitor. TVB-2640 is rapidly absorbed in the human body with well-behaved pharmacokinetics.

Pipeline

FASN Inhibitor

Indication

Preclinical

Phase 1

Phase 2

Phase 3

TVB-2640

NASH

Title

58%

TVB-2640

Oncology

Title

58%

TVB-3567

Undisclosed

Title

22%

FASN Inhibitor – TVB-2640

Indication – NASH

Phase 2

Title

70%

FASN Inhibitor – TVB-2640

Indication – Oncology

Phase 2

Title

70%

FASN Inhibitor – TVB-3567

Indication – Undisclosed

Preclinical

Title

30%

Posters & Publications

December 18, 2019 in PUBLICATIONS

First‐in‐class fatty acid synthase inhibitor TVB‐2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities

Read More
September 6, 2019 in PUBLICATIONS

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

Read More
September 5, 2019 in PUBLICATIONS

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

Read More